# Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

> **NCT01059565** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 102 (actual)

## Conditions studied

- Cystic Fibrosis
- Burkholderia Infections

## Interventions

- **DRUG:** AZLI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01059565
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-09
- **Final completion:** 2012-01
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059565, "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01059565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*